Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business

Hurley, Berks, UK, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, Astellas”) and LEO Pharma A/S (President and CEO: Gitte P. Aabo, “LEO Pharma”) today announced that the two companies completed the relevant closing conditions on March 31, 2016 to allow the transfer of the Astellas global dermatology business to LEO Pharma from 0 a.m. on April 1.

Click here to view the full press release in pdf format.

 

Cookies on this site

LEO Laboratories Limited uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing our sites, you consent to the use of cookies. If you want to know more about our cookie policy and how to avoid and delete cookies click here. By continuing to browse this site, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.